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Aims: To assess the quality of histopathology reporting and accuracy of Dukes’s staging of colorectal
cancers in the former South Western Health region and to determine the impact of numbers of lymph
nodes examined on stage ascription.
Methods: Histopathology reports of colorectal cancer for 1993–7 were analysed. Completeness was
assessed regarding reported numbers of lymph nodes examined, numbers found positive, Dukes’s stage,
and ICD9 code. Numbers of lymph nodes examined, numbers found positive, and Dukes’s stage were
recorded. Results from one hospital known to have high standards of reporting were compared with those
from elsewhere.
Results: In total, 629 reports were examined from the reference hospital and 918 from elsewhere. Fewer
than one in 20 (4.3%) reports from the reference hospital were incomplete, compared with a third (36.1%)
elsewhere. The average number of nodes examined for each case at the reference hospital was 18.81 and
6.41 elsewhere. The average number of positive nodes for each case was 2.47 at the reference hospital
and 1.15 elsewhere. The proportion of Dukes’s stage C cases was significantly higher at the reference
hospital than elsewhere. Ascertainment of Dukes’s stage C cases was related to number of lymph nodes
examined, with optimal ascertainment levels when at least 10 and fewer than 15 nodes were examined.
Conclusions: Standards of histopathology reporting, and ascertainment of Dukes’s stage C, were
significantly higher at the reference hospital. Variations in ascertainment levels of Dukes’s stage C disease
mainly resulted from variations in the numbers of lymph nodes examined.
I
mproving the quality of services for colorectal cancer is a
national priority. National performance indicators have
been defined, including the quality of pathology, and one
of the objectives of the National standards for cancer treatment
is ‘‘pathology reports conforming to Royal College of
Pathologist’s recommendations for individual cancer sites’’.1
The Royal College of Pathologist’s minimum dataset includes
number of lymph nodes examined and the number found
positive. It recommends that all lymph nodes draining the
lymphatic field of a colorectal cancer should be harvested for
histological assessment.2
The incidence of colorectal cancer has increased greatly in
recent years. For example, in 1992 the incidence of colon
cancer for each 100 000 population had risen to 34.16 from
22.47 in men in 1973, and to 38.10 from 29.58 in women.3 A
total of 25 000 cases of colorectal cancer occur annually in the
UK; 80% are resected surgically.4 There are resource problems
associated with this large and increasing workload. Pollock
et al have drawn attention to the extent to which the relative
risk of not being treated increased between 1982 and 1988 in
the South Thames regions.5 The increasing workload is
undoubtedly a major factor in explaining the results of an
audit of histopathology laboratories in Wales during 1993,
which indicated that the information content of many reports
was inadequate for high quality patient management or
clinical audit.6 For example, only 51.5% of rectal cancer
reports indicated completeness of excision, and only 30% of
all reports stated the number of involved lymph nodes.
Overall, only 11.3% of reports on colonic tumours and 4.0% of
reports on rectal tumours contained all previously agreed
data items.6
European cancer registry based comparisons suggest that
there may be inadequate treatment of patients with colorectal
cancer in the UK. However, it has been intimated that the
poor UK survival rates can be explained by more advanced
stage at presentation, although this has been challenged.7 The
EUROCARE study indicated that there was still a twofold
variation in survival rates after adjustment for variations in
stage distribution.8 An Italian study has shown that survival
improvements between 1984 and 1995 were related to an
increasing proportion of early stage disease.9 However,
tumours may be understaged and hence excluded from
certain forms of treatment, such as adjuvant treatment,
through failure to identify lymph node involvement.10
‘‘Because the classification of a cancer as Dukes’s C is
wholly determined by lymph node involvement, the
importance of accurate lymph node assessment is
irrefutable’’
Delays in diagnosis and treatment probably result in
tumours being more advanced when treatment is begun.
More advanced stage is associated with poorer survival. The
National Health Service Executive guidance on improving
outcomes in colorectal cancer reports a case series from
Dublin in which around 30% of patients presented with
Dukes’s stage C cancers; among these, five year survival was
about 30%,11 although this could be improved with protracted
systemic chemotherapy.11 In that regard, Dukes’s staging
remains the single most important determinant of the
decision to institute adjuvant chemotherapy in younger,
fitter patients. Thus, systemic chemotherapy is generally
indicated for Dukes’s C cancers, whereas the indications for
such treatment in Dukes’s B cancers are more uncertain.12
Because the classification of a cancer as Dukes’s C is wholly
determined by lymph node involvement, the importance of
accurate lymph node assessment is irrefutable.
There are pronounced variations between pathologists in
ascription of resection specimens to Dukes’s stage A or B on
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the one hand, or Dukes’s C on the other.4 13 Improvements in
accuracy may result from following standardised specimen
examination methods,14 15 including formal proformas.16 17 It
has been suggested that peroperative lymphatic mapping and
identification of sentinel lymph nodes may lead to improve-
ments in staging18 and more tailored resections.19 In one
study, such an approach resulted in upstaging 18% of
patients.20
There have been several studies that have arrived at
different conclusions regarding the number of lymph nodes
that should be examined to ensure accurate stage ascription.
The recommendations of these studies differ in detail, partly
but not entirely because different criteria have been adopted,
but generally agree that the more extensive the lymph node
harvest the greater is the chance of discovery of metastatic
disease within those lymph nodes.
METHODS
Our study was undertaken in the former South Western
Health region to assess the accuracy of Dukes’s staging in
colorectal cancer. This was accomplished by comparing
results achieved in one hospital that was known to have
achieved a high standard of accuracy in this regard
(henceforth ‘‘hospital A’’) with data from other hospitals in
the region. The enquiry had two main foci: (1) the quality of
histopathology reporting and (2) the assignment of cases to
Dukes’s stages A or B, on the one hand, and stage C on the
other, and the impact on stage ascription of numbers of
lymph nodes examined.
Histopathology reports relating to cases of colorectal cancer
were collected from hospitals across the region, for the five
year period 1993–7, through the South Western Regional
Cancer Registry and also by direct contact with laboratories.
Completeness was assessed in respect of numbers of lymph
nodes examined and numbers found positive, Dukes’s stage,
and site code (ICD9). For those reports where sufficient detail
was recorded, numbers of lymph nodes examined, numbers
found positive, and Dukes’s stage were recorded. Results in
the exemplar site, hospital A, were compared with those
elsewhere in the region.
There were 629 reports available from hospital A and 918
from the other hospitals. The comparability of the cases
drawn from hospital A and the other hospitals was assessed
by studying the distribution of numbers of cases by ICD9 site
codes in the two groups. Numbers of lymph nodes examined
in the two groups of cases were recorded. Mean values and
95% confidence intervals (CI) were calculated and a Mann-
Whitney test of rank distribution carried out. The proportions
of cases with Dukes’s C staging were ascertained in the two
groups and the extent to which differences could be
explained by variations in the number of lymph nodes
examined was determined.
RESULTS
Overall, 629 reports were examined from hospital A, of which
27 were incomplete in some respect, whereas 918 reports
were examined from the other hospitals, of which 331 were
incomplete. Table 1 summarise the results in respect of
completeness. There were large and significant differences
between the reference hospital and the others. Overall, more
than a third (36.1%) of the records from hospitals other than
the reference hospital were incomplete in one or more aspect,
compared with fewer than one in 20 (4.3%) at the reference
hospital.
The distribution of numbers of cases by ICD9 site code was
similar in hospital A and the other hospitals, indicating that
the two patient populations were broadly comparable. There
was a very substantial difference between hospital A and the
other hospitals in numbers of lymph nodes examined
(table 2). The average number of nodes examined for each
patient at hospital A was 18.81 (95% CI, 18.07 to 19.55),
whereas at the other hospitals it was 6.41 (95% CI, 6.09 to
6.73). A similar significant difference was also seen for
numbers of positive lymph nodes encountered (table 3), the
average number for each patient at hospital A being 2.47
(95% CI, 2.11 to 2.83) and at other hospitals 1.15 (95% CI,
0.08 to 1.31). However, a Mann-Whitney test of rank
Table 1 Hospital A versus the other hospitals: incomplete records
Records
Hospital A Other hospitals
TotalNo. cases % (95% CI) No. cases % (95% CI)
Incomplete report 27 4.30 (2.68 to 5.92) 331 36.10 (32.92 to 39.27) 358
Suboptimal record of nodes examined,
nodes positive, and Dukes’s stage
10 1.59 (0.59 to 2.59) 161 17.56 (15.04 to 20.07) 171
No record of Dukes’s stage but can be inferred 1 0.16 (0.00 to 0.48) 42 4.58 (3.20 to 5.96) 43
No record of nodes examined/positive
but Dukes’s stage given
9 1.43 (0.48 to 2.38) 35 3.82 (2.55 to 5.08) 44
Nodes examined and nodes positive recorded
but Dukes’s stage not given
0 0.00 24 2.62 (1.56 to 3.67) 24
Missing ICD code 11 1.75 (0.70 to 2.80) 57 6.22 (4.62 to 7.81) 68
Total 628 100.0 917 100.0 1545
CI, confidence interval.




Hospital A Other hospitals
TotalNo. patients % (95% CI) No. patients % (95% CI)
1–9 88 14.55 (11.68 to 17.41) 498 80.32 (77.13 to 83.52) 586
10–14 129 21.32 (17.99 to 24.65) 89 14.35 (11.54 to 17.17) 218
15–19 131 21.65 (18.30 to 25.00) 27 4.35 (2.72 to 5.99) 158
20 or more 257 42.48 (38.46 to 46.50) 6 0.97 (0.18 to 1.75) 263
Total 605 100.0 620 100.0 1225
CI, confidence interval.
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distribution showed no association between numbers of
lymph nodes examined and the likelihood of having lymph
node involvement. This may be because it is a test of
difference in central tendency between two groups and does
not work well if they differ without a difference in average
rank position, as in this case, where node negative cases
appear to form a higher proportion of cases in both the higher
and the lower ranks.
The proportion of Dukes’s stage C cases was 7.95% higher
at the reference hospital than elsewhere (50.24% at hospital
A; 42.29% elsewhere). This was significant at the 95% level
(table 4). Ascertainment of Dukes’s stage C cases was related
to the number of lymph nodes examined, with optimal
ascertainment levels occurring when at least 10 and fewer
than 15 nodes were examined. This was true at both hospital
A and the other hospitals (table 5). The proportion of cases
from hospital A was closely correlated with the number of
nodes examined (R = 0.967; explained variation, 93.5%),
whereas 68.7% of the overall variation in the proportion of
Dukes’s stage C tumours with numbers of lymph nodes
examined can be explained as being the result of variations in
the proportion of cases from hospital A (R = 0.828).
DISCUSSION
In our study, the observed variation in pathological reporting
quality is consistent with other studies, which have con-
cluded that standard proformas and more precisely defined
staging may be appropriate.21 There is general agreement on
the need to improve standards of reporting, in particular
stage ascription, to improve clinical care, and of the benefits
of standard protocols, such as that of the Cancer Committee
of the College of American Pathologists.22 Following the
Welsh audit, suggestions for improving the quality of
pathological reporting included the use of template profor-
mas,6 to improve among other things the quality of clinical
decision making, especially the use of postoperative adjuvant
treatment.23 Indeed, more recent evidence has confirmed that
the routine use of proformas substantially improves the
recording of relevant data.17 Much of the inadequacy of
colorectal cancer reporting has been attributed to poor
teaching in macroscopic assessment, resulting in inadequate
lymph node harvesting, poor evaluation of local spread, and
unsatisfactory determination of margin and serosal involve-
ment.4
In our study, the number of Dukes’s C cases was
significantly higher (by about 8%) in the reference hospital
than in the other hospitals. Thus, it seem likely that, in the
former South Western Health region, excluding the popula-
tion served by hospital A, approximately 160 stage C cases
each year might have been understaged in this time period.
This has serious implications, because staging remains the
most important prognostic factor in colorectal cancer.
Furthermore, accurate staging is a very important prerequi-
site for effective treatment. Thus, adjuvant chemotherapy,
which has been proved to be of benefit in patients with
Dukes’s stage C colorectal cancer,24 has been associated with
a 34% improvement in disease free interval and a 29%
improvement in survival.25 This has been endorsed by the
National Health Service Executive’s guidance on improving
outcomes, which also argues that there is insufficient
evidence from randomised controlled trials to form a
definitive view on chemotherapy in stage B disease.11 More
recently, data from one of our centres has suggested that
accurate pathological assessment can successfully stratify
Dukes’s B colon cancers, at least, for prognosis, which may
aid in the selection of appropriate patients for adjuvant
treatment.12 It should also be noted that the effect of
understaging is to reduce artefactually the stage specific
survival of both stage B and stage C patients, through the
phenomenon of stage drift.
For both the exemplar hospital and the others, the
ascertainment of Dukes’s stage C disease was highest when
10 to 14 lymph nodes were examined. Examination of greater
numbers of lymph nodes brought no further improvement in
ascertainment levels. Ascertainment levels were lowest when
fewer than 10 lymph nodes were examined. The overall
difference in ascertainment of stage C disease between the
exemplar hospital and the others is mainly the result of the
fact that 80.32% of cases treated at other hospitals came into
the category of low lymph node harvests, compared with only
14.55% of cases treated at hospital A.
Table 3 Hospital A versus the other hospitals: distribution of patients by number of
positive lymph nodes encountered
Number of positive
nodes encountered
Hospital A Other hospitals
TotalNo. patients % (95% CI) No. patients % (95% CI)
0 305 50.83 (46.75 to 54.92) 411 58.38 (54.67 to 62.10) 716
1–4 181 30.17 (26.42 to 33.91) 247 35.09 (31.49 to 38.68) 428
5–9 77 12.83 (10.10 to 15.56) 38 5.40 (3.69 to 7.10) 115
10–14 19 3.17 (1.74 to 4.60) 7 0.99 (0.25 to 1.74)) 26
15–19 5 0.83 (0.09 to 1.58) 1 0.14 (0.00 to 0.43)) 6
20–24 10 1.67 (0.62 to 2.71) 0 – 10
25–29 1 0.17 (0.00 to 0.50) 0 – 1
30–34 2 0.33 (0.00 to 0.80) 0 – 2
Total 600 100.0 704 100.0 1304
CI, confidence interval.
Table 4 Hospital A versus the other hospitals: distribution of cases by Dukes’s stage
Dukes’s
stage
Hospital A Other hospitals
TotalNo. cases % (95% CI) No. cases % (95% CI)
A and B 307 49.76 (45.73 to 53.78) 419 57.71 (54.05 to 61.38) 726
C 310 50.24 (46.22 to 54.27) 307 42.29 (38.62 to 45.94) 617
Total 617 100.0 726 100.0 1343
CI, confidence interval.
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Various studies have considered how many lymph nodes to
examine. These are summarised in table 6.26–33
Our study suggests that at least 10 nodes should be
examined, but that ascertainment of stage C disease is not
improved by the examination of more than 15 nodes.
However, setting an artificial ‘‘ceiling’’ on lymph node
harvests by recommending minimum and maximum num-
bers has implicit dangers. Pathologists tend to initiate their
lymph node harvest at the ‘‘high tie’’ and work towards the
tumour. Inevitably, therefore, probable reactive nodes, close
to the high tie and away from the tumour, will be harvested
first. If the minimum lymph node number is reached and no
further dissection undertaken, then it is highly conceivable
that the less than diligent pathologist will miss those nodes
that are most likely to contain metastatic disease. Ultimately,
we would concur with a recent comprehensive study of
lymph node harvests, in a single USA centre, which found
that there was no safe minimum number that could
guarantee identification of node involvement, and which
recommended that all lymph nodes in the lymphatic field of a
colorectal cancer should be removed for histopathological
assessment.31
‘‘For both the exemplar hospital and the others, the
ascertainment of Dukes’s stage C disease was highest
when 10 to 14 lymph nodes were examined’’
Inevitably the many studies that have assessed colorectal
cancer lymph node harvests rely heavily on the technique
used to obtain those lymph nodes. In general, in the UK at
least, it is recommended that lymph nodes are harvested after
adequate fixation and by ‘‘bacon slicing’’ the mesorectum/
mesocolon into 2–5 mm slices. We would particularly
advocate removing the fatty tissues from the bowel wall
first, although we would accept that this does make
assessment of the extent of direct spread of the tumour,
either towards a surgical margin, as in the rectum, or to the
serosal aspect, more problematic, especially when harvesting
nodes close to the tumour. Very few centres, in the UK at
least, use fat clearing techniques, and there is evidence to
indicate that these do not increase the yield of involved
Table 6 Recommendations about numbers of lymph nodes to examine in colorectal
cancer resection specimens
Fist author (Ref) Year of publication Study objective No. lymph nodes
Hermanek26 1993 Maximise ascertainment of Dukes’s stage C
disease
20+
Goldstein27 1996 Maximise detection of nodal metastases 17–20
Maurel28 1998 Optimal ascription to node positive or node
negative categories
8+
Cserni29 1999 Maximise proportion of node positive cases 6–16
Wong30 1999 Generate stage distribution comparable with
US National Cancer Data Base report
14
Goldstein31 2002 Maximise detection of nodal metastases All available
Johnson32 2002 Conformity to American Joint Committee on
Cancer recommendations
12
Cserni33 2002 Reliability of node negative ascription All available
Table 5 Percentage of Dukes’s stage C cases, by number of nodes examined, for hospital







Dukes A/B Dukes C
No. cases % Total (95% CI) No. cases % Total (95% CI)
A 1–9 88 52 59.09 (48.61 to 69.57) 36 40.91 (30.43 to 51.39)
10–14 129 50 38.76 (30.18 to 47.34) 79 61.24 (52.66 to 69.82)
15–19 131 67 51.15 (42.41 to 59.88) 64 48.85 40.12 to 57.59)
>20 257 131 50.97 (44.74 to 57.21) 126 49.03 (42.79 to 55.26)
Total 605 300 49.59 (45.54 to 53.65) 305 50.41 (46.35 to 54.48)
Others 1–9 498 291 58.43 (54.02 to 62.85) 207 41.57 (37.15 to 45.98)
10–14 89 44 49.44 (38.84 to 60.04) 49 55.06 (38.44 to 60.04)
15–19 27 14 51.85 (32.62 to 71.08) 13 48.15 (28.92 to 67.38
>20 6 3 50.00 (9.18 to 90.82) 3 50.00 (9.18 to 90.82)
Total 620 352 56.77 (52.80 to 60.75) 272 43.87 (39.89 to 47.86)
CI, confidence interval.
Take home messages
N We assessed the quality of histopathology reporting
and accuracy of Dukes’s staging of colorectal cancers,
comparing hospitals in the former South Western
Health region with a ‘‘reference’’ hospital known to
have high standards of reporting
N Standards of histopathology reporting and ascertain-
ment of Dukes’s stage C were significantly higher at the
reference hospital
N Variations in ascertainment levels of Dukes’s stage C
disease mainly resulted from variations in the numbers
of lymph nodes examined, and this could have serious
consequences for individual patients, who may be
denied life saving adjuvant chemotherapy
N Mean lymph node harvests above 10 would maximise
the number of cases ascribed to Dukes’s stage C,
although lymph node harvests above 15 did not
significantly increase the ascription to this stage
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lymph nodes.34 Optimal harvests demand the motivation, and
above all else, the time of the pathologist. We have no doubt
that time and motivation, rather than individual methods,
are the two most important factors to ensure adequate lymph
node harvests.4
In conclusion, our study has shown that low lymph node
harvests will lead to a reduction in the number of Dukes’s C
cases, which in turn has serious consequences for individual
patients, who may be denied life saving adjuvant chemother-
apy. The findings compliment others studies in the literature
and show that mean lymph node harvests above 10 will
maximise the number of cases ascribed to Dukes’s stage C,
although lymph node harvests above 15 did not significantly
increase the ascription to this stage. In the UK, at least,
determined efforts at education and the introduction of
proforma reporting and datasets have improved the recording
of important pathological prognostic data in colorectal
cancer: we await further studies to determine whether the
quality of that data has substantially improved.
ACKNOWLEDGEMENTS
We acknowledge with thanks all the histopathologists throughout
the former South Western Health region who supplied pathology
reports of colorectal cancer resection specimens for this audit.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
D F H Pheby, Unit of Applied Epidemiology, University of the West of
England, Frenchay Campus, Coldharbour Lane, Bristol BS16 1QY, UK
D F Levine, West Cornwall Hospital, St Clare Street, Penzance, Cornwall
TR18 2PF, UK
R W Pitcher, Department of Histopathology, Royal Cornwall Hospital,
Truro, Cornwall TR1 3LJ, UK
N A Shepherd, Department of Histopathology, Gloucestershire Royal
Hospital, Great Western Road, Gloucester GL1 3NN, UK
REFERENCES
1 Executive NHS. Improving the quality of cancer services. HSC 2000/021 June
2001.
2 Quirke P, Williams GT. Minimum dataset for colorectal cancer histopathology
reports. London: Royal College of Pathologists, 2000.
3 EUROCIM database v 3.0. Lyon: IARC, 1999.
4 Shepherd NA, Quirke P. Colorectal cancer reporting: are we failing the
patient? J Clin Pathol 1997;50:266–7 .
5 Pollock AM, Benster R, Vickers N. Why did treatment rates for colorectal
cancer in South East England fall between 1982 and 1988? The effect of case
ascertainment and registration bias. J Public Health Med 1995;17:419–428.
6 Bull AD, Biffin AH, Melia J, et al. Colorectal cancer pathology reporting: a
regional audit. J Clin Pathol 1997;50:138–42.
7 Woodman CB, Gibbs A, Scott N, et al. Are differences in stage at presentation
a credible explanation for reported differences in the survival of patients with
colorectal cancer in Europe? Br J Cancer 2001;85:787–90.
8 Gatta G, Capocaccia R, Sant M, et al. Understanding variations in survival for
colorectal cancer in Europe: a EUROCARE high resolution study. Gut
2000;47:533–8.
9 Ponz de Leon M, Benatti P, Percesepe A, et al. Epidemiology of cancer of the
large bowel—the 12-year experience of a specialized registry in northern
Italy. Ital J Gastroenterol Hepatol 1999;31:10–18.
10 Ratto C, Sofo L, Ippoliti M, et al. Accurate lymph-node detection in colorectal
specimens resected for cancer is of prognostic significance. Dis Colon Rectum
1999;42:143–54.
11 NHS Executive. Guidance on commissioning cancer services: improving
outcomes in colorectal cancer—the manual. London: Department of Health,
October 2001.
12 Petersen VC, Baxter KJ, Love SB, et al. Identification of objective pathological
prognostic determinants and models of prognosis in Dukes B colon cancer.
Gut 2002;51:65–9.
13 Jass JR, Ajioka Y, Allen JP, et al. Assessment of invasive growth pattern
and lymphocytic infiltration in colorectal cancer. Histopathology
1996;28:543–8.
14 Hermanek P, Giedl J, Dworak O. Two programmes for examination of
regional lymph nodes in colorectal carcinoma with regard to the new pN
classification. Pathol Res Pract 1989;185:867–73.
15 Cserni G, Tarjan M, Bori R. Distance of lymph nodes from the tumor: an
important feature in colorectal cancer specimens. Arch Pathol Lab Med
2001;125:246–9.
16 Rigby K, Brown SR, Lakin G, et al. The use of a proforma improves colorectal
cancer pathology reporting. Ann R Coll Surg Engl 1999;81:401–3.
17 Cross SS, Feeley KM, Angel CA. The effect of four interventions on the
informational content of histopathology reports of resected colorectal
carcinomas. J Clin Pathol 1998;51:481–2.
18 Wiese DA, Saha S, Badin J, et al. Pathologic evaluation of sentinel lymph
nodes in colorectal carcinoma. Arch Pathol Lab Med 2000;124:1759–63.
19 Thorn M. Lymphatic mapping and sentinel node biopsy: is the method
applicable to patients with colorectal and gastric cancer? Eur J Surg
2000;166:755–8.
20 Saha S, Wiese D, Badin J, et al. Technical details of sentinel lymph node
mapping in colorectal cancer and its impact on staging. Ann Surg Oncol
2000;7:120–4.
21 Raraty MG, Winstanley JH. Variation in the staging of colorectal carcinomas:
a survey of current practice. Ann R Coll Surg Engl 1998;80:188–91.
22 Compton CC, Henson DE, Hutter RV, et al. Updated protocol for the
examination of specimens removed from patients with colorectal carcinoma. A
basis for checklists. Arch Pathol Lab Med 1997;121:1247–54.
23 Jass JR. Future role of the pathologist in reporting colorectal cancer.
World J Surg 1997;21:688–93.
24 Rayter Z, Leicester RJ, Mansi JL. Adjuvant chemotherapy for colorectal cancer.
Ann R Coll Surg Engl 1995;77:81–4.
25 Ratkin GA. Adjuvant therapy for colon and rectal cancer. Am Fam Physician
1997;55:2487–92.
26 Hermanek P, Henson DE, Hutter RVP, et al. Appendix II. Colorectal
carcinoma. UICC TNM supplement—a commentary on uniform use. Berlin:
Springer-Verlag, 1993:69–71.
27 Goldstein NS, Sanford W, Coffey M, et al. Lymph node recovery from
colorectal resection specimens removed for adenocarcinoma; trends over time
and a recommendation for a minimum number of lymph nodes to be
recovered. Am J Clin Pathol 1996;106:209–16.
28 Maurel J, Launoy G, Grosclaude P, et al. Lymph node harvest reporting in
patients with carcinoma of the large bowel: a French population-based study.
Cancer 1998;82:1482–6.
29 Cserni G, Vajda K, Tarjan M, et al. Nodal staging of colorectal carcinomas
from quantitative and qualitative aspects. Can lymphatic mapping help
staging? Pathol Oncol Res 1999;5:291–6.
30 Wong JH, Severino R, Honnebier MB, et al. Number of nodes examined and
staging accuracy in colorectal carcinoma. J Clin Oncol 1999;17:2896–900.
31 Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection
specimens spanning 45 years: recommendations for a minimum number of
recovered lymph nodes based on predictive probabilities. Am J Surg Pathol
2002;26:179–89.
32 Johnson PM, Malatjalian D, Porter GA. Adequacy of nodal harvest in
colorectal cancer: a consecutive cohort study. J Gastrointest Surg
2002;6:883–8.
33 Cserni G, Vinh-Hung V, Burzykowski T. Is there a minimum number of lymph
nodes that should be histologically assessed for a reliable nodal staging of
T3N0M0 colorectal carcinomas? J Surg Oncol 2002;81:63–9.
34 Jass JR, Miller K, Northover JMA. Fat clearance method versus manual
dissection of lymph nodes in specimens of rectal cancer. Int J Colorectal Dis
1986;1:155–6.
Lymph node harvests and colorectal cancer staging 47
www.jclinpath.com
